Research Papers:

Blockade of telomerase reverse transcriptase enhances chemosensitivity in head and neck cancers through inhibition of AKT/ERK signaling pathways

Tengda Zhao _, Fengchun Hu, Xingguang Liu and Qian Tao

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2015; 6:35908-35921. https://doi.org/10.18632/oncotarget.5468

Metrics: PDF 1636 views  |   HTML 1954 views  |   ?  


Tengda Zhao1,2, Fengchun Hu1,3, Xingguang Liu1, Qian Tao1

1Department of Oral and Maxillofacial Surgery, Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, Guangdong, China

2Department of Oral and Maxillofacial Surgery, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China

3Department of Stomatology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China

Correspondence to:

Qian Tao, e-mail: [email protected]

Keywords: TERT, HNSCC, AKT, ERK, chemosensitivity

Received: April 10, 2015     Accepted: October 06, 2015     Published: October 16, 2015


Head and Neck squamous cell carcinomas (HNSCC), characterized by the high frequency of local recurrence and distant metastases, is mostly related to highly malignant and resistant to apoptosis, resulting in significant insensitivity to chemotherapy. Telomerase reverse transcriptase (TERT), as the catalytic subunit of telomerase, was implicated in the telomerase-mediated cellular transformation, proliferation, stemness and cell survival. Moreover, overexpression of human TERT (hTERT) is reported to be correlated with advanced invasive stage of the tumor progression and poor prognosis. Here, we show that hTERT potentially mediated the apoptotic resistance and blockade of telomerase reverse transcriptase could enhance chemosensitivity in head and neck cancers. Mechanistically, hTERT interacts with the phosphorylation of AKT and ERK to suppress the expression of p53, ultimately, leading to modulation of the cellular sensitivity to chemotherapy. Thus, these findings suggest that hTERT targeting could be an attractive approach in combination with conventional chemotherapies for patients suffering from chemoinsensitivity or refractory HNSCC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5468